bromfenac 0.09%

DRUG2 trials

Sponsors

Frank A. Bucci, Jr., M.D., Bucci Laser Vision Institute

Conditions

CataractsPost Operative Anterior Chamber Inflammation (Flare)

Phase 4

A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification

CompletedNCT01001806

Frank A. Bucci, Jr., M.D.Cataracts

Start: 2009-10-31End: 2010-01-31Updated: 2011-10-03

A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

CompletedNCT01023724

Bucci Laser Vision InstitutePost Operative Anterior Chamber Inflammation (Flare)

Start: 2009-12-31End: 2010-02-28Updated: 2011-08-26